Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cells ; 11(22)2022 11 11.
Article in English | MEDLINE | ID: mdl-36428990

ABSTRACT

Chemotherapy-induced neuropathic pain is a debilitating and dose-limiting side effect. Oxaliplatin is a third-generation platinum and antineoplastic compound that is commonly used to treat colorectal cancer and commonly yields neuropathic side effects. Available drugs such as duloxetine provide only modest benefits against oxaliplatin-induced neuropathy. A particularly disruptive symptom of oxaliplatin is painful cold sensitivity, known as cold allodynia. Previous studies of the Conus regius peptide, RgIA, and its analogs have demonstrated relief from oxaliplatin-induced cold allodynia, yielding improvement that persists even after treatment cessation. Moreover, underlying inflammatory and neuronal protection were shown at the cellular level in chronic constriction nerve injury models, consistent with disease-modifying effects. Despite these promising preclinical outcomes, the underlying molecular mechanism of action of RgIA4 remains an area of active investigation. This study aimed to determine the necessity of the α9 nAChR subunit and potential T-cell mechanisms in RgIA4 efficacy against acute oxaliplatin-induced cold allodynia. A single dose of oxaliplatin (10 mg/kg) was utilized followed by four daily doses of RgIA4. Subcutaneous administration of RgIA4 (40 µg/kg) prevented cold allodynia in wildtype mice but not in mice lacking the α9 nAChR-encoding gene, chrna9. RgIA4 also failed to reverse allodynia in mice depleted of CD3+ T-cells. In wildtype mice treated with oxaliplatin, quantitated circulating T-cells remained unaffected by RgIA4. Together, these results show that RgIA4 requires both chrna9 and CD3+ T-cells to exert its protective effects against acute cold-allodynia produced by oxaliplatin.


Subject(s)
Drug-Related Side Effects and Adverse Reactions , Neuralgia , Receptors, Nicotinic , Animals , Mice , Oxaliplatin/adverse effects , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Neuralgia/chemically induced , Neuralgia/drug therapy
2.
J Med Chem ; 64(13): 9271-9278, 2021 07 08.
Article in English | MEDLINE | ID: mdl-34142837

ABSTRACT

Venom-derived compounds are of broad interest in neuropharmacology and drug development. α-Conotoxins are small disulfide-containing peptides from Conus snails that target nicotinic acetylcholine receptors (nAChRs) and are in clinical development for non-opioid-based treatment of intractable pain. Although refined by evolution for interaction with target prey receptors, enhancements of pharmacological properties are needed for use in mammalian systems. Therefore, we synthesized analogues of α-conotoxin RgIA using a combination of selective penicillamine substitutions together with natural and non-natural amino acid replacements. This approach resulted in a peptide with 9000-fold increased potency on the human α9α10 nAChR and improved resistance to disulfide shuffling compared to the native peptide. The lead analogue, RgIA-5474, potently blocked α9α10 nAChRs, but not opioid- or other pain-related targets. In addition, RgIA-5474 effectively reversed chemotherapy-induced neuropathic pain.


Subject(s)
Analgesics/pharmacology , Conotoxins/pharmacology , Drug Development , Neuralgia/drug therapy , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/metabolism , Analgesics/chemical synthesis , Analgesics/chemistry , Conotoxins/chemical synthesis , Conotoxins/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Neuralgia/metabolism , Nicotinic Antagonists/chemical synthesis , Nicotinic Antagonists/chemistry , Structure-Activity Relationship
3.
Biochem Pharmacol ; 181: 114124, 2020 11.
Article in English | MEDLINE | ID: mdl-32593612

ABSTRACT

The α9α10 nicotinic acetylcholine receptor (nAChR) has been characterized as an effective anti-pain target that functions through a non-opioid mechanism. However, as a pentameric ion channel comprised of two different subunits, the specific targeting of α9α10 nAChRs has proven challenging. Previously the 13-amino-acid peptide, RgIA, was shown to block α9α10 nAChRs with high potency and specificity. This peptide, characterized from the venom of the carnivorous marine snail, Conus regius, produced analgesia in several rodent models of chronic pain. Despite promising pre-clinical data in behavioral assays, the number of specific α9α10 nAChR antagonists remains small and the physiological mechanisms of analgesia remain cryptic. In this study, we implement amino-acid substitutions to definitively characterize the chemical properties of RgIA that contribute to its activity against α9α10 nAChRs. Using this mutational approach, we determined the vital role of biochemical side-chain properties and amino acids in the second loop that are amenable to substitutions to further engineer next-generation analogs for the blockade of α9α10 nAChRs.


Subject(s)
Amino Acid Substitution , Amino Acids/genetics , Conotoxins/genetics , Receptors, Nicotinic/metabolism , Amino Acid Sequence , Amino Acids/chemistry , Amino Acids/metabolism , Animals , Binding Sites/genetics , Conotoxins/metabolism , Conotoxins/pharmacology , Humans , Mollusk Venoms/chemistry , Mollusk Venoms/metabolism , Nicotinic Antagonists/metabolism , Nicotinic Antagonists/pharmacology , Oocytes/drug effects , Oocytes/metabolism , Oocytes/physiology , Protein Subunits/antagonists & inhibitors , Protein Subunits/genetics , Protein Subunits/metabolism , Rats , Receptors, Nicotinic/genetics , Sequence Homology, Amino Acid , Xenopus laevis
4.
Mar Drugs ; 18(1)2019 Dec 21.
Article in English | MEDLINE | ID: mdl-31877728

ABSTRACT

Chemotherapeutic drugs are widely utilized in the treatment of human cancers. Painful chemotherapy-induced neuropathy is a common, debilitating, and dose-limiting side effect for which there is currently no effective treatment. Previous studies have demonstrated the potential utility of peptides from the marine snail from the genus Conus for the treatment of neuropathic pain. α-Conotoxin RgIA and a potent analog, RgIA4, have previously been shown to prevent the development of neuropathy resulting from the administration of oxaliplatin, a platinum-based antineoplastic drug. Here, we have examined its efficacy against paclitaxel, a chemotherapeutic drug that works by a mechanism of action distinct from that of oxaliplatin. Paclitaxel was administered at 2 mg/kg (intraperitoneally (IP)) every other day for a total of 8 mg/kg. Sprague Dawley rats that were co-administered RgIA4 at 80 µg/kg (subcutaneously (SC)) once daily, five times per week, for three weeks showed significant recovery from mechanical allodynia by day 31. Notably, the therapeutic effects reached significance 12 days after the last administration of RgIA4, which is suggestive of a rescue mechanism. These findings support the effects of RgIA4 in multiple chemotherapeutic models and the investigation of α9α10 nicotinic acetylcholine receptors (nAChRs) as a non-opioid target in the treatment of chronic pain.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Conotoxins/pharmacology , Neuralgia/drug therapy , Neuralgia/etiology , Paclitaxel/adverse effects , Animals , Humans , Hyperalgesia/drug therapy , Male , Nicotinic Antagonists/pharmacology , Rats , Rats, Sprague-Dawley
5.
Ther Clin Risk Manag ; 6: 65-75, 2010 Mar 03.
Article in English | MEDLINE | ID: mdl-20234786

ABSTRACT

Current national and international asthma guidelines recommend treatment of children with asthma towards achieving and maintaining asthma control. These guidelines provide more stringent recommendations to increase therapy for patients with uncontrolled asthma in order to reduce asthma-related morbidity and mortality. Newer combination agents such as budesonide and formoterol have been shown to be safe and effective in treatment of asthma in children. Use of long-term controller agents like this in combination with improved compliance and treatment of co-morbid conditions have been successful in this endeavor. This review discusses control of pediatric asthma with focus on the use of budesonide in combination with formoterol.

SELECTION OF CITATIONS
SEARCH DETAIL
...